JWJianrong Wu

Jianrong Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianrong Wu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

    by Wayne Lee Furman, Barry L. Shulkin, Sara Michele Federico, Mary B McCarville, Andrew M. Davidoff, Matthew J. Krasin, Jianrong Wu, Rachel Christine Brennan, Michael William Bishop, Sara E. Helmig, et al.

    10534 Background: We are conducting a Phase II trial of the anti-GD2 mAb hu14.18K322A given concomitantly with CT in newly diagnosed pts with HR NB. Our primary objective is to compare the response rate (RR; defined as ≥ PR) after two courses of CT with cyclophosphamide (CTX)/topotecan (TPT) and hu14.18K322A with GM-CSF and IL-2 to the RR reported by Park et al. (JCO 29:4351, 2011), using identical CT with GCSF only, in a two-stage group sequential design. Semiquantitative MIBG scoring (Curie; CS) has been shown to be a prognostic indicator of outcome in pts with HR NB (Yanik et al, J Nucl Med, 2013), particularly, those with CS > 2 at end of induction (EoI) CT have inferior outcomes. Here we update the RR and report the CS at EoI CT. Methods: Pts received induction CT (6 cycles) as described by Park et al, with the addition of hu14.18K332A (on d 2-5; 40mg/m2/d x 4d), daily sc GM-CSF and sc IL-2 (1 x 106 IU/m2/dose) qod x 6. 123I-MIBG scans and scoring (CS) were obtained on all pts at diagnosis, after second course of CT and at EoI. Results: 42 evaluable pts completed the first two courses of CT (24 male, median age 2.9 yrs (range 6 m -15.2 yrs), 36 INSS 4, 19 MYCNamplified); 40/42 evaluable pts had measurable reductions in primary tumor volume after two courses of CT (median 79%, average 69%, range +5 – 100%). Responses (≥ PR) after two courses were seen in 32/42 (76.2%; 95% CI 61.3 – 87.9%); No mAb dose-reductions were made but 20/43 (47%) pts had infusion times extended. The development of human anti-human antibody reactivity (HAHA) to hu14.18K322A in the first 22 pts is minimal. Of the 36 INSS 4 pts, 1 withdrew prior to EoI and 2 are too early. The median CS at diagnosis for the 33 stage 4 pts who have completed induction CT was 18 (range 1 – 28). At EoI the median CS was 0 (range 0 -23); 29/33 INSS 4 pts had EoI CS ≤ 2. Conclusions: The addition of hu14.18K322A to two courses of CTX/TPT significantly improves the RR compared to two courses of CTX/TPT alone (32/42 vs 12/30 as reported by Park et al,; P = 0.000004). The improved median CS of the stage 4 patients from 18 at diagnosis to 0 at EoI suggest the improvement in early RR may translate into improved EFS as well. Clinical trial information: NCT01857934.


  • A simulation-based sample size calculation method for pre-clinical tumor xenograft experiments

    by Jianrong Wu, Shengping Yang

    Pre-clinical tumor xenograft experiments usually require a small sample size that is rarely greater than 20, and data generated from such experiments very often do not have censored observations. Many statistical tests can be used for analyzing such data, but most of them were developed based on large sample approximation. We demonstrate that the type-I error rates of these tests can substantially deviate from the designated rate, especially when the data to be analyzed has a skewed distribution. Consequently, the sample size calculated based on these tests can be erroneous. We propose a modified signed log-likelihood ratio test (MSLRT) to meet the type-I error rate requirement for analyzing pre-clinical tumor xenograft data. The MSLRT has a consistent and symmetric type-I error rate that is very close to the designated rate for a wide range of sample sizes. By simulation, we generated a series of sample size tables based on scenarios commonly expected in tumor xenograft experiments, and we expect that these tables can be used as guidelines for making decisions on the numbers of mice used in tumor xenograft experiments.

  • Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test

    by Jianrong Wu, Xiaoping Xiong

    For randomized group sequential survival trial designs with unbalanced treatment allocation, the widely used Schoenfeld formula is inaccurate, and the commonly used information time as the ratio of number of events at interim look to the number of events at the end of trial can be biased. In this article, a sample size formula for the two-sample log-rank test under the proportional hazards model is proposed that provides more accurate sample size calculation for unbalanced survival trial designs. Furthermore, a new information time is introduced for the sequential survival trials such that the new information time is more accurate than the traditional information time when the allocation of enrollments is unbalanced in groups. Finally, we demonstrate the monitoring process using the sequential conditional probability ratio test and compare it with two other well-known group sequential procedures. An example is given to illustrate unbalanced survival trial design using available software. Supplementary materials for this article are available online.


  • Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model

    by Jianrong Wu

    For designing single-arm phase II trials with time-to-event endpoints, a sample size formula is derived for the modified one-sample log-rank test under the proportional hazards model. The derived formula enables new methods for designing trials that allow a flexible choice of the underlying survival distribution. Simulation results showed that the proposed formula provides an accurate estimation of sample size. The sample size calculation has been implemented in an R function for the purpose of trial design. Supplementary materials for this article are available online.


  • A novel sample size formula for the weighted log‐rank test under the proportional hazards cure model

    by Xiaoping Xiong, Jianrong Wu

    The treatment of cancer has progressed dramatically in recent decades, such that it is no longer uncommon to see a cure or log‐term survival in a significant proportion of patients with various types of cancer. To adequately account for the cure fraction when designing clinical trials, the cure models should be used. In this article, a sample size formula for the weighted log‐rank test is derived under the fixed alternative hypothesis for the proportional hazards cure models. Simulation showed that the proposed sample size formula provides an accurate estimation of sample size for designing clinical trials under the proportional hazards cure models.


  • Survival trial design and monitoring using historical controls

    by Jianrong Wu, Xiaoping Xiong

    In this paper, we propose a multistage group sequential procedure to design survival trials using historical controls. The formula for the number of events required for historical control trial designs is derived. Furthermore, a transformed information time is proposed for trial monitoring. An example is given to illustrate the application of the proposed methods to survival trial designs using historical controls. Copyright © 2016 John Wiley & Sons, Ltd.


  • Sample size calculation for testing differences between cure rates with the optimal log-rank test

    by Jianrong Wu

    In this article, sample size calculations are developed for use when the main interest is in the differences between the cure rates of two groups. Following the work of Ewell and Ibrahim, the asymptotic distribution of the weighted log-rank test is derived under the local alternative. The optimal log-rank test under the proportional distributions alternative is discussed, and sample size formulas for the optimal and standard log-rank tests are derived. Simulation results show that the proposed formulas provide adequate sample size estimation for trial designs and that the optimal log-rank test is more efficient than the standard log-rank test, particularly when both cure rates and percentages of censoring are small.


  • Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors.

    by Sara Michele Federico, Mary B McCarville, Clinton F. Stewart, Shenghua Mao, Jianrong Wu, Andrew M. Davidoff, Wayne Lee Furman, Victor M. Santana, Alberto S. Pappo, Fariba Navid

    10519 Background: Angiogenesis is required for tumor growth and metastasis. Both VEGF and PDGFR are key regulators of tumor vasculature. In preclinical models, dual inhibition of VEGF and PDGFR signaling result in more effective tumor suppression and improved survival. We report the results of an expansion cohort of a phase I study targeting angiogenesis with sorafenib, bevacizumab and low-dose cyclophosphamide in children and young adults with solid tumors. Methods: The treatment doses and schedule of the combined therapy were derived from results of a previously reported dose-escalation phase I study (Navid F et al. Clin Cancer Res 2013). Four cohorts of 6 patients with refractory or recurrent solid tumors were enrolled and received bevacizumab (15mg/kg IV, day 1), sorafenib (90mg/m2 po BID, days 1-21) and low-dose cyclophosphamide (50mg/m2 po daily, days 1-21). Each course of therapy lasted 21 days. Serial bevacizumab pharmacokinetic (PK) studies were performed during course 1. Toxicity was assessed using CTCAE 3.0. Response was assessed using RECIST1.1. Results: Twenty-four patients (15 males; median age 14.5 yrs; range 1.1-22.4 yr) received a median of 6 courses (range 1-18) of therapy. Twelve patients had a bone or soft tissue sarcoma and 12 patients had a non-sarcoma solid tumor. The most common grade 3/4 non-hematologic toxicities were hypertension (4), hand/foot rash (3) and elevated lipase (3). The most common grade 3/4 hematologic toxicities were neutropenia (7) and lymphopenia (17). Three patients (2 synovial sarcoma, 1 rhabdoid tumor) achieved a partial response and 18 had disease stabilization. The progression-free survival at 3 and 6 months were 78.1% (95% CI 60.6-95.6%) and 54% (95% CI 30.2-78.2%). Bevacizumab PK studies were performed in 15 patients and the median (range) clearance, Cmax, Tmax and AUC were 4.4mL/day/kg (2.8-6.0), 331µg/mL (206-441), 1.9hrs (1.6-4.6) and 3345µg/mL*day (2566-5297) respectively. Conclusions: This treatment regimen is well tolerated and demonstrated promising activity in a variety of childhood solid tumors. Additional studies are warranted. Clinical trial information: NCT00665990.

  • Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study.

    by Wayne Lee Furman, Sara Michele Federico, Mary B McCarville, Andrew M. Davidoff, Matthew J. Krasin, Jianrong Wu, Rachel Christine Brennan, Michael William Bishop, Victor M. Santana, Armita Bahrami, et al.

    10501 Background: The chimeric anti-GD2 mAb dinutuximab improves EFS in HR NB when administered in the setting of minimal residual disease following intensive chemotherapy (CT) (Yu et al. NEJM 2010). We evaluated the feasibility and activity of a humanized anti-GD2 mAb with a single point mutation (K322A) that reduces complement-dependent lysis, hu14.18K322A, given concomitantly with CT in newly diagnosed children with HR NB. Methods: Patients (pts) received induction CT (6 cycles) as described by Park (JCO 29:4351, 2011; induction CT used in most recent COG HR NB trial) with hu14.18K332A (on d 2-5 40mg/m2/d x 4d), GM-CSF and low dose IL-2. The primary objective was to compare the response rate (RR) after the initial two courses of CT with cyclophosphamide (CTX)/topotecan (TPT) and hu14.18K322A to the RR reported by Park et al., using identical CT with granulocyte colony-stimulating factor and without hu14.18K322A, GM-CSF and IL-2, in a two-stage group sequential design. Results: At the interim analysis of 20 evaluable pts, (10 male; median age 34 m (range 6 – 180 m), 16 INSS stage 4, 12 MYCN amplified), all pts had significant benefit. The RR after the first two courses of therapy was 80% (95% CI 56%-94%) with 15 PRs, 1 VGPR and 4 with SD (primary tumor volume decreased by 47, 75, 81 and 96%); Pain from the anti-GD2 mAb was well controlled by continuous infusion narcotics initiated prior to the start of hu14.18K322A and adjusted as needed. Eleven of 21 pts had hu14.18K322A infusions extended because of the development of cough, hypoxia and/or hypotension. All pts received all planned doses of hu14.18K322A. Conclusions: The addition of hu14.18K322A to two courses of CTX / TPT is well tolerated and has significant activity (16/20 (80%) ≥ PR) compared to 12/30 (40%) ≥ PR reported by Park et al. in a similar group of pts who received two courses of CTX/TPT alone (p = 0.0057). Accrual is ongoing. Anti-GD2 mAbs given concomitantly with CT warrant further evaluation. Clinical trial information: NCT01857934.


  • Single-arm Phase II cancer survival trial designs

    by Jianrong Wu

    The current practice for designing single-arm Phase II trials with time-to-event endpoints is limited to using either a maximum likelihood estimate test under the exponential model or a naive approach based on dichotomizing the event time at a landmark time point. A trial designed under the exponential model may not be reliable, and the naive approach is inefficient. The modified one-sample log-rank test statistic proposed in this article fills the void. In general, the proposed test can be used to design single-arm Phase II survival trials under any parametric survival distribution. Simulation results showed that it preserves type I error well and provides adequate power for Phase II cancer trial designs with time-to-event endpoints.